Ampyra (Fampridine / Dalfampridine) Extended-Release Tablets

Ampyra (dalfampridine, also known as fampridine), from Acorda Therapeutics, is a potassium-channel blocker indicated to improve walking in adults with multiple sclerosis, as demonstrated by an increase in walking speed. It is the only medicine specifically approved for this purpose.

Dalfampridine blocks potassium channels on nerve fibers, which helps strengthen the conduction of electrical signals along demyelinated (damaged) nerves in MS, improving the transmission of nerve impulses that control movement.

• Seizure risk is increased, particularly at doses above the recommended amount or in patients with reduced kidney function.
• Contraindicated in patients with a history of seizures.
• Renal function should be assessed before and periodically during treatment.
• Common side effects: urinary tract infection, insomnia, dizziness, headache, nausea, weakness.

What documents are required to import Ampyra to India?

Ampyra may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered neurologist
• Diagnostic report confirming multiple sclerosis and kidney function status
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.

Is Ampyra available in India?

Ampyra is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source Ampyra from Acorda Therapeutics’ authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For Ampyra cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA — January 2010.

What is Ampyra used for?

Ampyra improves walking speed in adults with multiple sclerosis.

Who manufactures Ampyra?

Ampyra is manufactured by Acorda Therapeutics, Inc.

How is Ampyra dosed?

One 10 mg extended-release tablet twice daily, about 12 hours apart — never more than this due to seizure risk.

How much does Ampyra cost in India?

Cost depends on monthly quantity and sourcing logistics — share your prescription with IPN for a quote.